ACE-27, Adult Comorbidity Evaluation 27

  • 文章类型: Journal Article
    UNASSIGNED:分析有关老年人中高危前列腺癌(PC)放射治疗的文献。
    UNASSIGNED:进行了PubMed文献检索,其中包括2000年1月1日至21年6月30日的文章,关键字如下:PC,放射治疗/近距离放射治疗和老年人。分析主要集中在老年人治疗不足的问题和辐射的利益/风险平衡。
    未经评估:在分析的176个参考文献中,24符合选择标准。“老年患者”的定义从70岁到80岁不等。分析受到每个队列中使用的不均匀主要终点的影响。年龄通常是激进治疗的障碍,随后有治疗不足的风险,特别是在预后较差的患者中。然而,将可比较的老年肿瘤结局与年轻患者进行比较,无论是单独使用外束放射治疗还是结合近距离放射治疗。晚期毒性率低,通常与年轻人群相当。然而,超老年人(>80岁)在加强近距离放射治疗后观察到尿毒性过度。应根据合并症考虑使用ADT,甚至可能对某些患者有害。
    未经评估:由于预期寿命的增加,老年人的PC管理对患者来说是一个挑战,临床医生和医疗保险付款人。除了不适合的男人,老年患者在进行老年病学评估后仍可选择最佳治疗方案(即不论年龄大小).来自专门针对该人群进行的前瞻性试验的更可靠数据将为我们的日常临床实践提供更好的指导。
    UNASSIGNED: To analyze the literature that addresses radiation therapy for intermediate and high-risk prostate cancer (PC) in the elderly.
    UNASSIGNED: A PubMed literature search was conducted including articles from 01/01/2000 to 30/06/21, with the following keywords: PC, radiotherapy/brachytherapy and elderly. The analysis mainly focused on the issue of under-treatment in the elderly and the benefit/risk balance of irradiation.
    UNASSIGNED: Of the 176 references analyzed, 24 matched the selection criteria. The definition of \"elderly patient\" varied from 70 to 80 years. The analysis was impacted by the inhomogeneous primary end points used in each cohort. Age was often an obstacle to radical treatment, with a subsequent risk of under-treatment, particularly in patients with a poorer prognosis. However, comparable elderly oncological outcomes were compared to younger patients, both with external beam radiotherapy alone or combined with brachytherapy boost. Late toxicity rates are low and most often comparable to younger populations. However, a urinary over- toxicity was observed in the super-elderly (>80 years) after brachytherapy boost. The use of ADT should be considered in light of comorbidities, and may even be deleterious in some patients.
    UNASSIGNED: Due to the increase in life expectancy, the management of PC in the elderly is a challenge for patients, clinicians and health insurance payers. Except for unfit men, elderly patients remain candidates for optimal curative treatment (i.e. regardless of age) after oncogeriatric assessment. More solid data from prospective trials conducted specially in this population will provide better guidance in our daily clinical practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    吞咽困难是常见的,头颈部肿瘤治疗后的严重和剂量限制性毒性(HNC)。本研究旨在研究治疗性(化学)放射治疗(RT)后HNC患者的正常吞咽结构与患者报告的放射剂量之间的关系以及临床测量的吞咽功能,重点是后期效果。
    2007-2015年接受RT±化疗治疗的HNC患者(n=90)通过电话访谈和视频透视(VFS)评估治疗后吞咽困难。研究特定的症状评分用于确定患者报告的吞咽困难。应用穿透抽吸量表(PAS)通过VFS确定吞咽功能(PAS≥4/≥6=中度/重度吞咽困难)。在患者的原始计划CT扫描和检索的相关剂量-体积直方图(DVH)上分别描绘了正常吞咽中涉及的13个解剖结构。通过单变量和多变量逻辑回归分析(UVA/MVA)研究了结构剂量与晚期毒性之间的关系,并考虑了相关临床因素的影响。
    中位评估时间为RT后7个月(范围:5-34个月)。对侧腮腺和声门上喉的平均剂量以及对侧前腹肌的最大剂量预测了患者报告的吞咽困难(AUC=0.64-0.67)。咽缩肌的平均剂量,喉部,声门上喉和会厌,以及对侧颌下腺的最大剂量通过VFS预测了中度和重度吞咽困难(AUC=0.71-0.80)。
    该队列中的患者在治疗前被连续识别,并在治疗后的特定时间点进行结构接近和评估吞咽困难。除了确定的吞咽困难危险器官(OAR),我们的数据表明,会厌和颌下腺剂量对RT后吞咽功能很重要.保持DVH阈值低于V60=60%和V60=17%,分别,可能会增加机会,以减少严重的晚期吞咽困难的发生。结果需要在未来的研究中进行外部验证。
    UNASSIGNED: Dysphagia is a common, severe and dose-limiting toxicity after oncological treatment of head and neck cancer (HNC). This study aims to investigate relationships between radiation doses to structures involved in normal swallowing and patient-reported as well as clinically measured swallowing function in HNC patients after curative (chemo-) radiation therapy (RT) with focus on late effects.
    UNASSIGNED: Patients (n = 90) with HNC curatively treated with RT ± chemotherapy in 2007-2015 were assessed for dysphagia post-treatment by telephone interview and videofluoroscopy (VFS). A study-specific symptom score was used to determine patient-reported dysphagia. The Penetration-Aspiration Scale (PAS) was applied to determine swallowing function by VFS (PAS ≥ 4/ ≥ 6 = moderate/severe dysphagia). Thirteen anatomical structures involved in normal swallowing were individually delineated on the patients\' original planning CT scans and associated dose-volume histograms (DVHs) retrieved. Relationships between structure doses and late toxicity were investigated through univariable and multivariable logistic regression analysis (UVA/MVA) accounting for effects by relevant clinical factors.
    UNASSIGNED: Median assessment time was 7 months post-RT (range: 5-34 months). Mean dose to the contralateral parotid gland and supraglottic larynx as well as maximum dose to the contralateral anterior digastric muscle predicted patient-reported dysphagia (AUC = 0.64-0.67). Mean dose to the pharyngeal constrictor muscle, the larynx, the supraglottic larynx and the epiglottis, as well as maximum dose to the contralateral submandibular gland predicted moderate and severe dysphagia by VFS (AUC = 0.71-0.80).
    UNASSIGNED: The patients in this cohort were consecutively identified pre-treatment, and were structurally approached and assessed for dysphagia after treatment at a specific time point. In addition to established dysphagia organs-at-risk (OARs), our data suggest that epiglottic and submandibular gland doses are important for swallowing function post-RT. Keeping DVH thresholds below V60 = 60% and V60 = 17%, respectively, may increase chances to reduce occurrence of severe late dysphagia. The results need to be externally validated in future studies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号